CD8A and neoplasm: The combination of InVivoMab and RT significantly increased tumor infiltration of CD4+ (12.05 ± 7.35%) and CD8+ (31.09 ± 3.82%) cells compared with the control groups (0.72 ± 0.21%, 9.68 ± 5.04%, respectively), indicating enhanced recruitment and activation of effector T cells.